[
  {
    "title": "易瑞生物2022年预计净利1.1亿–1.5亿同比下降37%-53% 新冠类产品毛利下滑较大",
    "href": "http://stock.jrj.com.cn/2023/01/06215137265610.shtml",
    "datetime": "2023-01-06 21:51:09",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)2022年度净利润预降36.58%-53.49%",
    "href": "http://stock.jrj.com.cn/2023/01/06180637264907.shtml",
    "datetime": "2023-01-06 18:06:52",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：布鲁氏菌cELISA抗体检测试剂盒取得兽药产品批准文号",
    "href": "http://stock.jrj.com.cn/2023/01/03181337256030.shtml",
    "datetime": "2023-01-03 18:13:50",
    "code": "300942"
  },
  {
    "title": "易瑞生物控股股东朱海质押450万股 用于个人资金需求",
    "href": "http://stock.jrj.com.cn/2022/12/21211137229584.shtml",
    "datetime": "2022-12-21 21:11:56",
    "code": "300942"
  },
  {
    "title": "易瑞生物：芬太尼药物滥用检测试剂盒通过美国FDA 510(K)审核",
    "href": "http://stock.jrj.com.cn/2022/12/16184537218972.shtml",
    "datetime": "2022-12-16 18:45:18",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：秀朴生物的“芬太尼药物滥用检测试剂盒(荧光层析法)”通过美国FDA510(K)审核",
    "href": "http://stock.jrj.com.cn/2022/12/16183637218958.shtml",
    "datetime": "2022-12-16 18:36:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物声明：严格要求经销商等合作方服从国家疫情防控政策",
    "href": "http://stock.jrj.com.cn/2022/12/11074937203687.shtml",
    "datetime": "2022-12-11 07:49:46",
    "code": "300942"
  },
  {
    "title": "A股异动 | 易瑞生物(300942.SZ)跌近7% 林季敏完成减持0.5%股份 拟继续减持不超100万股",
    "href": "http://stock.jrj.com.cn/2022/12/05113037188074.shtml",
    "datetime": "2022-12-05 11:30:37",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：林季敏完成减持0.5%股份 拟继续减持不超100万股",
    "href": "http://stock.jrj.com.cn/2022/12/02185737185395.shtml",
    "datetime": "2022-12-02 18:57:18",
    "code": "300942"
  },
  {
    "title": "【龙虎榜】易瑞生物12月2日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/12/02180837185142.shtml",
    "datetime": "2022-12-02 18:08:44",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：减持期过半 董事付辉累计减持184.96万股",
    "href": "http://stock.jrj.com.cn/2022/12/01203937182684.shtml",
    "datetime": "2022-12-01 20:39:51",
    "code": "300942"
  },
  {
    "title": "易瑞生物：取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/11/17192637147723.shtml",
    "datetime": "2022-11-17 19:26:37",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：甲基安非他明检测试剂盒(胶体金免疫层析法)取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/11/17182537147486.shtml",
    "datetime": "2022-11-17 18:25:34",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：四氢大麻酚酸检测试剂盒(胶体金免疫层析法)获医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/11/02180937107272.shtml",
    "datetime": "2022-11-02 18:09:41",
    "code": "300942"
  },
  {
    "title": "易瑞生物：获得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/11/02180137107217.shtml",
    "datetime": "2022-11-02 18:01:32",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：持股2%股东林季敏拟减持不超0.5%股份",
    "href": "http://stock.jrj.com.cn/2022/10/31181337100542.shtml",
    "datetime": "2022-10-31 18:13:51",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：子公司4项产品取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/10/23182737075991.shtml",
    "datetime": "2022-10-23 18:27:40",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：全程C-反应蛋白(hsCRP+常规CRP)测定试剂盒(荧光免疫层析法)取得注册证",
    "href": "http://stock.jrj.com.cn/2022/10/19181237067654.shtml",
    "datetime": "2022-10-19 18:12:13",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：股东卢和华减持期届满未减持",
    "href": "http://stock.jrj.com.cn/2022/10/10203037045153.shtml",
    "datetime": "2022-10-10 20:30:16",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：减持期届满 红杉智盛累计减持2.23%股份",
    "href": "http://stock.jrj.com.cn/2022/10/10202837045121.shtml",
    "datetime": "2022-10-10 20:28:43",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：子公司取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/09/27175137025377.shtml",
    "datetime": "2022-09-27 17:51:23",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)上半年净利1.51亿元，同比下降7.28%",
    "href": "http://stock.jrj.com.cn/2022/08/29213936949260.shtml",
    "datetime": "2022-08-29 21:39:20",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：减持计划提前终止 董事、副总付辉已减持100股",
    "href": "http://stock.jrj.com.cn/2022/08/09202736884255.shtml",
    "datetime": "2022-08-09 20:27:49",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：董事、副总付辉拟减持不超371.65万股",
    "href": "http://stock.jrj.com.cn/2022/08/09202736884258.shtml",
    "datetime": "2022-08-09 20:27:28",
    "code": "300942"
  },
  {
    "title": "易瑞生物总经理卢和华辞职 肖昭理接任 2022年第一季度公司净利1.14亿",
    "href": "http://stock.jrj.com.cn/2022/07/29215036855570.shtml",
    "datetime": "2022-07-29 21:50:22",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：拟变更会计师事务所",
    "href": "http://stock.jrj.com.cn/2022/07/29194536855117.shtml",
    "datetime": "2022-07-29 19:45:23",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：聘任肖昭理为总经理",
    "href": "http://stock.jrj.com.cn/2022/07/29194336855123.shtml",
    "datetime": "2022-07-29 19:43:36",
    "code": "300942"
  },
  {
    "title": "易瑞生物：股东红杉智盛减持计划时间过半 已减持2.0153%公司股份",
    "href": "http://stock.jrj.com.cn/2022/07/08164536794784.shtml",
    "datetime": "2022-07-08 16:45:22",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：2名董事、高管减持期过半 仅付辉减持100股",
    "href": "http://stock.jrj.com.cn/2022/07/08162536794660.shtml",
    "datetime": "2022-07-08 16:25:23",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：红杉智盛减持期已过半 累计减持2.0153%股份",
    "href": "http://stock.jrj.com.cn/2022/07/08162236794665.shtml",
    "datetime": "2022-07-08 16:22:57",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：新冠病毒抗原检测试剂盒(乳胶免疫层析法)获得CE证书",
    "href": "http://stock.jrj.com.cn/2022/05/26192236682181.shtml",
    "datetime": "2022-05-26 19:22:20",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)2021年度分红派息10派2.49元 股权登记日为5月27日",
    "href": "http://stock.jrj.com.cn/2022/05/20184136666748.shtml",
    "datetime": "2022-05-20 18:41:26",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：人类免疫缺陷病毒抗体检测试剂盒(胶体金免疫层析法)获得CE证书",
    "href": "http://stock.jrj.com.cn/2022/05/18192236659759.shtml",
    "datetime": "2022-05-18 19:22:44",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：红杉智盛已减持1.56623%的股份、持股降至4.99998%",
    "href": "http://stock.jrj.com.cn/2022/05/13202836647841.shtml",
    "datetime": "2022-05-13 20:28:39",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：红杉智盛股权投资已减持1.5156%的股份",
    "href": "http://stock.jrj.com.cn/2022/05/12215136644466.shtml",
    "datetime": "2022-05-12 21:51:36",
    "code": "300942"
  },
  {
    "title": "易瑞生物股东减持607.53万股 套现约1.4亿 2021年公司净利2.37亿",
    "href": "http://stock.jrj.com.cn/2022/05/12213236644363.shtml",
    "datetime": "2022-05-12 21:32:56",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：拟出资8900万元投设合伙企业深圳鼎瑞",
    "href": "http://stock.jrj.com.cn/2022/05/06192536582181.shtml",
    "datetime": "2022-05-06 19:25:58",
    "code": "300942"
  },
  {
    "title": "易瑞生物2022年第一季度净利1.14亿同比增长30.27% 体外诊断半成品业务收入增长",
    "href": "http://stock.jrj.com.cn/2022/05/03181136545938.shtml",
    "datetime": "2022-05-03 18:11:45",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)2021年度净利润升261.38%至2.37亿元 拟10派2.49元",
    "href": "http://stock.jrj.com.cn/2022/04/26210936478543.shtml",
    "datetime": "2022-04-26 21:09:29",
    "code": "300942"
  },
  {
    "title": "易瑞生物研发的新型冠状病毒抗原检测试剂盒取得医疗器械注册证 有效期一年",
    "href": "http://stock.jrj.com.cn/2022/03/24165234902319.shtml",
    "datetime": "2022-03-24 16:52:18",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110434892093.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435288093.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435306984.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435326416.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435336321.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435366470.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435460781.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435471352.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435514547.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435525747.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435572093.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435609298.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435660536.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435387330.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435407917.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435418128.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435548379.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435764841.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435777337.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435346374.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435356544.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435376906.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435397781.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435429417.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435450235.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435492677.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435634811.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435647765.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435673788.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435699856.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435712898.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435738669.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435278848.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435297456.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435316641.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435439719.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435481969.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435503522.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435537163.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435560154.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435584309.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435596687.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435622007.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435686795.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435725591.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新型冠状病毒抗原检测试剂盒取得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24110435749377.shtml",
    "datetime": "2022-03-24 11:04:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：新冠抗原检测试剂盒获得医疗器械注册证",
    "href": "http://stock.jrj.com.cn/2022/03/24082734887585.shtml",
    "datetime": "2022-03-24 08:27:43",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134887996.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134892103.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134893344.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134894635.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134897258.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134911637.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134929690.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134956533.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134982723.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135096843.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135114628.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135141385.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135150103.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135174972.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135184522.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135252094.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135278845.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135346359.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135366384.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135387242.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135481948.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135514521.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135525721.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135537137.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135634773.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135725558.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135738635.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135749246.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134847136.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134849381.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134865477.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134883105.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134885480.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134889372.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134920712.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134965359.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134999967.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135008574.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135052261.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135105697.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135123697.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135132712.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135193034.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135209702.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135397702.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135407850.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135450214.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135548348.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135560122.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135596655.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135660426.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135712862.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135777212.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135791162.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134832627.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134868163.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134870971.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134872304.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134873639.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134874904.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134878629.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134880947.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135025884.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135088025.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135158836.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135201493.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135218107.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135235023.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135243510.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135260784.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135288089.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135316634.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135356526.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135376816.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135439698.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135460760.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135471331.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135492655.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135686694.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135699821.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135764806.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134864705.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134866783.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134869537.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134876166.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134877417.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134879783.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134881939.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134884279.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134886723.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134890759.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134895912.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134902272.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134938697.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134947640.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134974055.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082134991353.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135017216.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135034622.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135043406.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135061248.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135070293.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135079148.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135167357.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135226582.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135269736.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135297452.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135306978.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135326406.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135336311.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135418048.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135429396.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135503498.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135572061.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135584277.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135609266.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135621974.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135647732.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物高管大股东合计减持680万股 疫情检测需求难续业绩增长",
    "href": "http://stock.jrj.com.cn/2022/03/16082135673755.shtml",
    "datetime": "2022-03-16 08:21:00",
    "code": "300942"
  },
  {
    "title": "A股异动 | 易瑞生物(300942.SZ)跌逾10% 新冠病毒抗原检测产品尚未取得国内医疗器械注册证书",
    "href": "http://stock.jrj.com.cn/2022/03/15134634828511.shtml",
    "datetime": "2022-03-15 13:46:51",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新冠抗原检测产品尚未取得国内注册证书 多名股东拟合计减持不超5.69%股份",
    "href": "http://stock.jrj.com.cn/2022/03/15100934827547.shtml",
    "datetime": "2022-03-15 10:09:49",
    "code": "300942"
  },
  {
    "title": "易瑞生物：新冠病毒抗原检测产品尚未取得国内医疗器械注册证书",
    "href": "http://stock.jrj.com.cn/2022/03/14200034825610.shtml",
    "datetime": "2022-03-14 20:00:05",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：2名董事、高管拟合计减持不超1.69%股份",
    "href": "http://stock.jrj.com.cn/2022/03/14195534825600.shtml",
    "datetime": "2022-03-14 19:55:19",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：红杉智盛拟减持不超4%股份",
    "href": "http://stock.jrj.com.cn/2022/03/14195234825590.shtml",
    "datetime": "2022-03-14 19:52:45",
    "code": "300942"
  },
  {
    "title": "【龙虎榜】易瑞生物3月14日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/03/14180234824850.shtml",
    "datetime": "2022-03-14 18:02:34",
    "code": "300942"
  },
  {
    "title": "【龙虎榜】易瑞生物2月28日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/02/28180334497534.shtml",
    "datetime": "2022-02-28 18:03:33",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：通过高新技术企业重新认定",
    "href": "http://stock.jrj.com.cn/2022/02/16183534370601.shtml",
    "datetime": "2022-02-16 18:35:56",
    "code": "300942"
  },
  {
    "title": "易瑞生物2021年预计净利2.2亿-2.6亿增长236%-297% 海外对新冠抗原自测试剂需求大增",
    "href": "http://stock.jrj.com.cn/2022/01/19215134175723.shtml",
    "datetime": "2022-01-19 21:51:11",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：2021年度净利预增236.16%-297.28%",
    "href": "http://stock.jrj.com.cn/2022/01/19194234175262.shtml",
    "datetime": "2022-01-19 19:42:54",
    "code": "300942"
  },
  {
    "title": "【龙虎榜】易瑞生物1月17日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/01/17180434165461.shtml",
    "datetime": "2022-01-17 18:04:23",
    "code": "300942"
  },
  {
    "title": "【龙虎榜】易瑞生物1月14日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/01/14180434158483.shtml",
    "datetime": "2022-01-14 18:04:01",
    "code": "300942"
  },
  {
    "title": "【龙虎榜】易瑞生物1月13日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/01/13180434154848.shtml",
    "datetime": "2022-01-13 18:04:25",
    "code": "300942"
  },
  {
    "title": "【龙虎榜】易瑞生物1月11日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/01/11180534146904.shtml",
    "datetime": "2022-01-11 18:05:10",
    "code": "300942"
  },
  {
    "title": "【龙虎榜】易瑞生物1月10日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/01/10180334142045.shtml",
    "datetime": "2022-01-10 18:03:54",
    "code": "300942"
  },
  {
    "title": "易瑞生物财务总监王广生辞职 万凯接任 第三季度公司净利3235.27万",
    "href": "http://stock.jrj.com.cn/2021/12/28193234077531.shtml",
    "datetime": "2021-12-28 19:32:54",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：财务总监王广生辞职 由万凯接任",
    "href": "http://stock.jrj.com.cn/2021/12/28082034074674.shtml",
    "datetime": "2021-12-28 08:20:32",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：向55名激励对象授予655万股限制性股票",
    "href": "http://stock.jrj.com.cn/2021/12/13201134010128.shtml",
    "datetime": "2021-12-13 20:11:28",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：朱海与王金玉已办理离婚手续 公司实控人变更为朱海",
    "href": "http://stock.jrj.com.cn/2021/11/16201833861779.shtml",
    "datetime": "2021-11-16 20:18:21",
    "code": "300942"
  },
  {
    "title": "易瑞生物前三季净利润增长277% 研发投入增五成 两大核心业务潜力大",
    "href": "http://stock.jrj.com.cn/2021/10/28083633767298.shtml",
    "datetime": "2021-10-28 08:36:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：拟使用不超5.5亿元闲置自有资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2021/09/23205733506521.shtml",
    "datetime": "2021-09-23 20:57:43",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：拟推2021年限制性股票激励计划",
    "href": "http://stock.jrj.com.cn/2021/09/23205633506514.shtml",
    "datetime": "2021-09-23 20:56:17",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)半年度净利润1.63亿元 同比增长316.45%",
    "href": "http://stock.jrj.com.cn/2021/08/25223133319511.shtml",
    "datetime": "2021-08-25 22:31:43",
    "code": "300942"
  },
  {
    "title": "易瑞生物2021年半年度净利1.63亿元 同比净利增加316.45%",
    "href": "http://stock.jrj.com.cn/2021/08/25201233318504.shtml",
    "datetime": "2021-08-25 20:12:21",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：249.51万股首发限售股8月9日解禁",
    "href": "http://stock.jrj.com.cn/2021/08/05173933207985.shtml",
    "datetime": "2021-08-05 17:39:04",
    "code": "300942"
  },
  {
    "title": "易瑞生物：上半年净利润预计同比增长283%-334%",
    "href": "http://stock.jrj.com.cn/2021/07/14093933093455.shtml",
    "datetime": "2021-07-14 09:39:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物2021年上半年预计净利1.5亿-1.7亿增长283%-334% 订单量大增",
    "href": "http://stock.jrj.com.cn/2021/07/13225133091378.shtml",
    "datetime": "2021-07-13 22:51:46",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)半年度净利润预增282.51%-333.51%",
    "href": "http://stock.jrj.com.cn/2021/07/13200033090725.shtml",
    "datetime": "2021-07-13 20:00:17",
    "code": "300942"
  },
  {
    "title": "易瑞生物拟对全资子公司秀朴生物增资1亿元",
    "href": "http://stock.jrj.com.cn/2021/06/29071233013763.shtml",
    "datetime": "2021-06-29 07:12:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：拟对秀朴生物增资1亿元",
    "href": "http://stock.jrj.com.cn/2021/06/28175433010921.shtml",
    "datetime": "2021-06-28 17:54:37",
    "code": "300942"
  },
  {
    "title": "易瑞生物控股股东易瑞控股质押750万股 用于融资",
    "href": "http://stock.jrj.com.cn/2021/06/23220032985418.shtml",
    "datetime": "2021-06-23 22:00:42",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：控股股东质押750万股",
    "href": "http://stock.jrj.com.cn/2021/06/23180132983972.shtml",
    "datetime": "2021-06-23 18:01:18",
    "code": "300942"
  },
  {
    "title": "易瑞生物：公司目前的产品应用暂未涉足医美领域",
    "href": "http://stock.jrj.com.cn/2021/06/11224432914300.shtml",
    "datetime": "2021-06-11 22:44:10",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：一项国家标准获批准发布",
    "href": "http://stock.jrj.com.cn/2021/05/28221732837213.shtml",
    "datetime": "2021-05-28 22:17:03",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)2020年度权益分派10派0.45元 股权登记日为6月1日",
    "href": "http://stock.jrj.com.cn/2021/05/26212632825540.shtml",
    "datetime": "2021-05-26 21:26:32",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：“宝安生物检测与诊断产业园”基坑支护、土石方工程由宏业基承包",
    "href": "http://stock.jrj.com.cn/2021/05/18185132777367.shtml",
    "datetime": "2021-05-18 18:51:12",
    "code": "300942"
  },
  {
    "title": "易瑞生物：公司快速检测产品中包含对化妆品中己烯雌酚、氯霉素等非法添加剂的检测",
    "href": "http://stock.jrj.com.cn/2021/05/14190432756698.shtml",
    "datetime": "2021-05-14 19:04:38",
    "code": "300942"
  },
  {
    "title": "易瑞生物：是否可用于居家检测属于产品应用场景的分类 与直接或间接测试没有直接相关的关系",
    "href": "http://stock.jrj.com.cn/2021/05/14190232756705.shtml",
    "datetime": "2021-05-14 19:02:47",
    "code": "300942"
  },
  {
    "title": "易瑞生物：公司一季报业绩增长主要是体外诊断业务相关原材料、半成品收入大幅增长",
    "href": "http://stock.jrj.com.cn/2021/05/14190032756709.shtml",
    "datetime": "2021-05-14 19:00:31",
    "code": "300942"
  },
  {
    "title": "易瑞生物：“世界卫生组织生产预认证建设项目”项目正在有序筹建中",
    "href": "http://stock.jrj.com.cn/2021/05/14184532756611.shtml",
    "datetime": "2021-05-14 18:45:35",
    "code": "300942"
  },
  {
    "title": "易瑞生物：公司目前业务暂不涉及生产、销售新冠检测试剂产成品",
    "href": "http://stock.jrj.com.cn/2021/05/14184032756518.shtml",
    "datetime": "2021-05-14 18:40:43",
    "code": "300942"
  },
  {
    "title": "易瑞生物：目前公司食品安全检测产品中暂时没有针对物体表面新冠病毒检测的相关产品",
    "href": "http://stock.jrj.com.cn/2021/05/14184032756516.shtml",
    "datetime": "2021-05-14 18:40:20",
    "code": "300942"
  },
  {
    "title": "易瑞生物：公司目前暂无生物安全的专门科研机构或科室",
    "href": "http://stock.jrj.com.cn/2021/05/14183832756496.shtml",
    "datetime": "2021-05-14 18:38:32",
    "code": "300942"
  },
  {
    "title": "【龙虎榜】易瑞生物4月28日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/04/28180532472853.shtml",
    "datetime": "2021-04-28 18:05:00",
    "code": "300942"
  },
  {
    "title": "【龙虎榜】易瑞生物4月27日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/04/27180332464211.shtml",
    "datetime": "2021-04-27 18:03:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物：公司目前暂时未涉及核污染检测领域",
    "href": "http://stock.jrj.com.cn/2021/04/25192532441966.shtml",
    "datetime": "2021-04-25 19:25:29",
    "code": "300942"
  },
  {
    "title": "易瑞生物：目前暂无针对核污染检测方面的产品",
    "href": "http://stock.jrj.com.cn/2021/04/25192432441963.shtml",
    "datetime": "2021-04-25 19:24:52",
    "code": "300942"
  },
  {
    "title": "易瑞生物：公司目前暂无新冠检测试剂产成品销售",
    "href": "http://stock.jrj.com.cn/2021/04/25192432441962.shtml",
    "datetime": "2021-04-25 19:24:50",
    "code": "300942"
  },
  {
    "title": "易瑞生物：公司目前没有涉及疫苗相关的业务",
    "href": "http://stock.jrj.com.cn/2021/04/25192432441961.shtml",
    "datetime": "2021-04-25 19:24:47",
    "code": "300942"
  },
  {
    "title": "【龙虎榜】易瑞生物4月23日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/04/23180232431070.shtml",
    "datetime": "2021-04-23 18:02:10",
    "code": "300942"
  },
  {
    "title": "【龙虎榜】易瑞生物4月22日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/04/22180332424592.shtml",
    "datetime": "2021-04-22 18:03:33",
    "code": "300942"
  },
  {
    "title": "易瑞生物2021年第一季度预计净利增长143%–157% 食品安全快检业务增长",
    "href": "http://stock.jrj.com.cn/2021/04/17204532391653.shtml",
    "datetime": "2021-04-17 20:45:09",
    "code": "300942"
  },
  {
    "title": "【龙虎榜】易瑞生物4月16日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/04/16180232387699.shtml",
    "datetime": "2021-04-16 18:02:51",
    "code": "300942"
  },
  {
    "title": "【龙虎榜】易瑞生物4月15日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/04/15180332380690.shtml",
    "datetime": "2021-04-15 18:03:44",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)一季度净利润预增142.65%-156.92%",
    "href": "http://stock.jrj.com.cn/2021/04/14203432373519.shtml",
    "datetime": "2021-04-14 20:34:28",
    "code": "300942"
  },
  {
    "title": "【龙虎榜】易瑞生物4月14日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/04/14180332372768.shtml",
    "datetime": "2021-04-14 18:03:11",
    "code": "300942"
  },
  {
    "title": "易瑞生物2020年度净利减少28.64% 汇率变动财务费用增加",
    "href": "http://stock.jrj.com.cn/2021/04/14135132371089.shtml",
    "datetime": "2021-04-14 13:51:42",
    "code": "300942"
  },
  {
    "title": "A股异动 | 易瑞生物(300942.SZ)跌近6% 2020年度净利润降28.64%",
    "href": "http://stock.jrj.com.cn/2021/04/14112832370249.shtml",
    "datetime": "2021-04-14 11:28:17",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)业绩快报：2020年度净利润降28.64%至6587.01万元",
    "href": "http://stock.jrj.com.cn/2021/04/13210132366996.shtml",
    "datetime": "2021-04-13 21:01:56",
    "code": "300942"
  },
  {
    "title": "【龙虎榜】易瑞生物4月13日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/04/13180432366057.shtml",
    "datetime": "2021-04-13 18:04:40",
    "code": "300942"
  },
  {
    "title": "易瑞生物：针对新冠病毒的检测公司在免疫学的平台上研发了一系列相关检测产品",
    "href": "http://stock.jrj.com.cn/2021/04/02182832271595.shtml",
    "datetime": "2021-04-02 18:28:43",
    "code": "300942"
  },
  {
    "title": "易瑞生物：公司新冠病毒检测产品暂未覆盖冷链食品表面检测的应用场景",
    "href": "http://stock.jrj.com.cn/2021/04/02182732271592.shtml",
    "datetime": "2021-04-02 18:27:08",
    "code": "300942"
  },
  {
    "title": "易瑞生物：公司新冠病毒检测产品暂未覆盖物品表面检测的应用场景",
    "href": "http://stock.jrj.com.cn/2021/04/02182432271580.shtml",
    "datetime": "2021-04-02 18:24:03",
    "code": "300942"
  },
  {
    "title": "易瑞生物：公司目前在深圳宝安暂无自有产权的房产",
    "href": "http://stock.jrj.com.cn/2021/04/02182332271579.shtml",
    "datetime": "2021-04-02 18:23:59",
    "code": "300942"
  },
  {
    "title": "【龙虎榜】易瑞生物3月9日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/03/09180832098772.shtml",
    "datetime": "2021-03-09 18:08:03",
    "code": "300942"
  },
  {
    "title": "易瑞生物：公司与华大基因、达安基因等公司不存在同业竞争的情形",
    "href": "http://stock.jrj.com.cn/2021/02/26190332034618.shtml",
    "datetime": "2021-02-26 19:03:44",
    "code": "300942"
  },
  {
    "title": "易瑞生物：目前8000万新冠检测试剂盒项目正在有序筹建中",
    "href": "http://stock.jrj.com.cn/2021/02/26190332034619.shtml",
    "datetime": "2021-02-26 19:03:12",
    "code": "300942"
  },
  {
    "title": "【龙虎榜】易瑞生物2月23日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/02/23180732013436.shtml",
    "datetime": "2021-02-23 18:07:30",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：拟使用不超4亿元部分闲置自有资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2021/02/21180031999505.shtml",
    "datetime": "2021-02-21 18:00:53",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：拟使用总额度不超1亿元部分暂时闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2021/02/21175931999500.shtml",
    "datetime": "2021-02-21 17:59:48",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：新增经营项目“检测仪器设备租赁”",
    "href": "http://stock.jrj.com.cn/2021/02/21175831999499.shtml",
    "datetime": "2021-02-21 17:58:34",
    "code": "300942"
  },
  {
    "title": "易瑞生物上市首日涨近6倍 龙虎榜卖出前4机构席位占3",
    "href": "http://stock.jrj.com.cn/2021/02/09214831879474.shtml",
    "datetime": "2021-02-09 21:48:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物上市盘中暴涨逾700% 中一签最高赚2.3万元",
    "href": "http://stock.jrj.com.cn/2021/02/09094431875586.shtml",
    "datetime": "2021-02-09 09:44:47",
    "code": "300942"
  },
  {
    "title": "今日新股上市：创识科技、易瑞生物、华康股份、太和水、四方光电",
    "href": "http://stock.jrj.com.cn/2021/02/09091331875412.shtml",
    "datetime": "2021-02-09 09:13:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)将于2月9日在创业板上市",
    "href": "http://stock.jrj.com.cn/2021/02/07213731862131.shtml",
    "datetime": "2021-02-07 21:37:55",
    "code": "300942"
  },
  {
    "title": "【兑奖啦】易瑞生物、创识科技等四新股网上申购中签号出炉",
    "href": "http://stock.jrj.com.cn/ipo/2021/02/01213431832147.shtml",
    "datetime": "2021-02-01 21:34:41",
    "code": "300942"
  },
  {
    "title": "新股申购：创识科技、易瑞生物、纵横股份、四方光电",
    "href": "http://stock.jrj.com.cn/ipo/2021/01/29091131806870.shtml",
    "datetime": "2021-01-29 09:11:40",
    "code": "300942"
  },
  {
    "title": "今日新股申购：创识科技、易瑞生物、纵横股份、四方光电",
    "href": "http://stock.jrj.com.cn/2021/01/29085831806783.shtml",
    "datetime": "2021-01-29 08:58:00",
    "code": "300942"
  },
  {
    "title": "创识科技、易瑞生物、纵横股份、四方光电1月29日申购",
    "href": "http://stock.jrj.com.cn/2021/01/28111631800099.shtml",
    "datetime": "2021-01-28 11:16:58",
    "code": "300942"
  },
  {
    "title": "易瑞生物(300942.SZ)：IPO拟发行4086万股 27日定价、29日申购",
    "href": "http://stock.jrj.com.cn/2021/01/21105931735248.shtml",
    "datetime": "2021-01-21 10:59:17",
    "code": "300942"
  },
  {
    "title": "证监会同意曼卡龙、春晖智控、易瑞生物、创识科技创业板IPO注册",
    "href": "http://stock.jrj.com.cn/2021/01/14164231692222.shtml",
    "datetime": "2021-01-14 16:42:13",
    "code": "300942"
  },
  {
    "title": "易瑞生物IPO：核心产品增长遭“天花板” 检测试剂质量不过关",
    "href": "http://stock.jrj.com.cn/2020/12/01070731381950.shtml",
    "datetime": "2020-12-01 07:07:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物IPO：核心产品增长遭“天花板” 检测试剂质量不过关",
    "href": "http://stock.jrj.com.cn/2020/12/01070731400811.shtml",
    "datetime": "2020-12-01 07:07:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物IPO：核心产品增长遭“天花板” 检测试剂质量不过关",
    "href": "http://stock.jrj.com.cn/2020/12/01070731408684.shtml",
    "datetime": "2020-12-01 07:07:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物IPO：核心产品增长遭“天花板” 检测试剂质量不过关",
    "href": "http://stock.jrj.com.cn/2020/12/01070731412133.shtml",
    "datetime": "2020-12-01 07:07:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物IPO：核心产品增长遭“天花板” 检测试剂质量不过关",
    "href": "http://stock.jrj.com.cn/2020/12/01070731402910.shtml",
    "datetime": "2020-12-01 07:07:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物IPO：核心产品增长遭“天花板” 检测试剂质量不过关",
    "href": "http://stock.jrj.com.cn/2020/12/01070731413840.shtml",
    "datetime": "2020-12-01 07:07:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物IPO：核心产品增长遭“天花板” 检测试剂质量不过关",
    "href": "http://stock.jrj.com.cn/2020/12/01070731426301.shtml",
    "datetime": "2020-12-01 07:07:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物IPO：核心产品增长遭“天花板” 检测试剂质量不过关",
    "href": "http://stock.jrj.com.cn/2020/12/01070731428604.shtml",
    "datetime": "2020-12-01 07:07:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物IPO：核心产品增长遭“天花板” 检测试剂质量不过关",
    "href": "http://stock.jrj.com.cn/2020/12/01070731430395.shtml",
    "datetime": "2020-12-01 07:07:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物IPO：核心产品增长遭“天花板” 检测试剂质量不过关",
    "href": "http://stock.jrj.com.cn/2020/12/01070731404843.shtml",
    "datetime": "2020-12-01 07:07:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物IPO：核心产品增长遭“天花板” 检测试剂质量不过关",
    "href": "http://stock.jrj.com.cn/2020/12/01070731406018.shtml",
    "datetime": "2020-12-01 07:07:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物IPO：核心产品增长遭“天花板” 检测试剂质量不过关",
    "href": "http://stock.jrj.com.cn/2020/12/01070731415926.shtml",
    "datetime": "2020-12-01 07:07:00",
    "code": "300942"
  },
  {
    "title": "易瑞生物IPO：核心产品增长遭“天花板” 检测试剂质量不过关",
    "href": "http://stock.jrj.com.cn/2020/12/01070731422065.shtml",
    "datetime": "2020-12-01 07:07:00",
    "code": "300942"
  }
]